期刊文献+

单核细胞趋化蛋白-1与糖尿病肾病 被引量:2

Relationship of monocyte chemoattractant protein-1 and diabetic nephropathy
原文传递
导出
摘要 糖尿病肾病(DN)是终末肾功能衰竭的主要原因,主要的病理改变是肾小球肥大、细胞外基质积聚以及。肾小球硬化。多种机制参与了DN的发生、发展,其中肾脏被炎性反应细胞如单核/巨噬细胞浸润是DN的标志之一。单核细胞趋化蛋白-1(MCP-1)是一种对单核细胞具有特异趋化功能的细胞因子,参与单核/巨噬细胞的浸润,在DN的发生、发展中起重要作用。 Diabetic nephropathy is the main reason leading to end-stage renal failure, the main pathological changes are glomerulus hypertrophy, accumulation of extracellular matrix and glomerulosclerosis. Many factors are involved in the development of diabetic nephropathy, and inflammatory cells, such as mono- cyte/macrophage infiltration in the kidney is one of symbols of diabetic nephropathy. Monocyte ehemoattractant protein-1 (MCP-1) is a kind of cytokines that exhibits most potent chemotactic activity toward monocytes. MCP-1 is suggested to be implicated in the development and progression of diabetic nephropathy by playing a role in infiltration of monocyte/macrophage.
出处 《国际内分泌代谢杂志》 2010年第6期408-410,共3页 International Journal of Endocrinology and Metabolism
基金 基金项目:辽宁省高等学校科研基金资助项目(2008800) 辽宁省自然科学基金资助项目(20072093)
关键词 糖尿病.肾病 单核细胞趋化蛋白-1 细胞因子 Diabetic nephropathy Monocyte chemoattractant protein-1 Cytokine
  • 相关文献

参考文献1

二级参考文献12

  • 1Dr. M.-L. Gross,A. El-Shakmak,A. Szábó,A. Koch,A. Kuhlmann,K. Münter,E. Ritz,K. Amann.ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy[J].Diabetologia.2003(6)
  • 2F. Bonnet,M. E. Cooper,H. Kawachi,T. J. Allen,G Boner,Z. Cao.Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension[J].Diabetologia.2001(7)
  • 3Doublier S,Salvidio G,Lupia E,Ruotsalainen V,Verzola D,Deferrari G,Camussi G.Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II[].Diabetes.2003
  • 4Aaltonen,P,Luimula,P,Astrom,E.Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy[].Laboratory Investigation.2001
  • 5Wu YG,Lin H,Qi XM,Wu GZ,Qian H,Zhao M,Shen JJ,Lin ST.Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes[].International Journal of Immunopharmacology.2006
  • 6Lewis,E.J.,Hunsicker,L.G.,Clarke,W.R.,Berl,T.,Pohl,M.A.,Lewis,J.B.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[].The New England Journal of Medicine.2001
  • 7Anderson S,Rennke HG.Brenner BM: Nifedipine versus fosinopril in uninephrectomized diabetic rats[].Kidney International.1992
  • 8Fujihara,CK,Malheiros,DM,Zatz,R,Noronha,ID.Mycophenolate mofetil attenuates renal injury in the rat remnant kidney[].Kidney International.1998
  • 9Soulis,T,Cooper,ME,Vranes,D,Bucala,R,Jerums,G.Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment[].Kidney International.1996
  • 10Fossati P,Prencipe L,Berti G.Enzymic creatinine assay: a new colorimetric method based on hydrogen peroxide measurement[].Clinical Chemistry.1983

共引文献22

同被引文献17

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部